Pfizer CEO Highlights Investment Hesitation Due to Tariff Uncertainty

Albert Bourla, CEO of Pfizer Inc., expressed concerns on Tuesday about the chilling effect of uncertain pharmaceutical tariffs proposed by US President Donald Trump on the company's expansion plans in the US. "The lack of clarity on tariffs is a significant barrier to making substantial investments in R&D and manufacturing within the country," Bourla stated.

The Impact of Uncertainty on Global Investments

Bourla elaborated on how unpredictability leads to cautious spending and restrained investment strategies. "In times of uncertainty, controlling costs becomes a priority, and investments are approached with extreme caution," he said, emphasizing the critical need for predictable policies to foster growth.

Financial Performance Amid Challenges

Despite these challenges, Pfizer reported an 8% increase in revenue to $13.7 billion in the first quarter of 2025. However, net income saw a 5% decline to $2.97 billion, with diluted earnings per share dropping to $0.52.